Data as of Sep 12, 2026. Both funds on the fields they both publish, from the same sources.
ILF vs XBI: how they differ
ILF and XBI hold 0% of their weight in the same names, and XBI returned more over the year.
iShares Latin America 40 ETF and State Street(R) SPDR(R) S&P(R) Biotech ETF.
What they hold in common
By the books each fund has filed, ILF and XBI hold 0% of their money in the same securities at the same weight.
| Only in ILF | Only in XBI |
|---|---|
| VALE S.A. 8.48% | Apogee Therapeutics Inc 1.49% |
| Nu Holdings Ltd. 8.25% | Moderna Inc 1.41% |
| Itau Unibanco Holding S.A. 7.11% | Twist Bioscience Corp 1.41% |
| Grupo Mexico, S.A.B. de C.V. 5.68% | Oruka Therapeutics Inc 1.38% |
| Petroleo Brasileiro S.A. (Petrobras) 5.19% | Kymera Therapeutics Inc 1.36% |
| Petroleo Brasileiro S.A. (Petrobras) 4.83% | Viking Therapeutics Inc 1.31% |
| CREDICORP LTD. 4.26% | Praxis Precision Medicines Inc 1.29% |
| Grupo Financiero Banorte, S.A.B. de C.V. 4.11% | Erasca Inc 1.27% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Jun 30, 2026.
| ILF iShares Latin America 40 ETF | XBI State Street(R) SPDR(R) S&P(R) Biotech ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | iShares | State Street |
| What it is | Latin America 40 | SPDR S&P Biotech |
| Total return, 1 year | +33.4% | +64.0% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | +15.9 pts | +46.5 pts |
| Expense ratio | 0.47% | 0.35% |
| Already in the S&P 500 | 0.0% | 8.5% |
| Holdings | 45 | 150 |
ILF in plain words
ILF is an index equity fund tracking the Latin America 40. Over the year to Sep 11, 2026 it returned +33.4% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.47% a year. By its holdings filed for Jun 30, 2026, 0% of the fund by weight is stocks the S&P 500 also holds, across 45 positions, with the top ten at 55.1%. It sat 4.4% below its high of Apr 14, 2026 on Sep 11, 2026.
XBI in plain words
XBI is an index equity fund tracking the SPDR S&P Biotech. Over the year to Sep 11, 2026 it returned +64.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.35% a year. By its holdings filed for Jun 30, 2026, 8% of the fund by weight is stocks the S&P 500 also holds, across 150 positions, with the top ten at 13.3%. It sat 9.6% below its high of Feb 8, 2021 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, ILF or XBI?
- In the year to Sep 12, 2026, with distributions reinvested, ILF returned +33.4% and XBI returned +64.0%, so XBI returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, ILF or XBI?
- ILF charges 0.47% a year and XBI charges 0.35%, so XBI is cheaper. Fees come from each fund's prospectus.
- How much do ILF and XBI overlap with the S&P 500?
- By their latest filed holdings, 0% of ILF and 8% of XBI by weight is stocks the S&P 500 already holds. Between the two funds, 0% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, ILF against XBI, data as of Sep 12, 2026. https://etfiq.com/compare/any/ILF-XBI Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources